Avoidant and Restrictive Food Intake Disorders (ARFID) in Adolescence: Early Oral Development, Psychopathological Profile and Sensory Integration (ARFIDOS)

April 30, 2026 updated by: Assistance Publique - Hôpitaux de Paris
The purpose of this study is to assess if adolescents affected with Avoidant and Restrictive Food Intake Disorders (ARFID) had more frequent precocious pediatric feeding disorders before 4 years old compared to healthy adolescents.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This research focuses on retrospective analysis of early pediatric feeding disorders seen for ARFID in adolescence in two departments of the DMU MEFADO.

This assessment will be implemented during a hospital visit by a questionnaire completed by the patient's parents covering the first years of the child's life in medical, behavioural and dietary terms. This questionnaire was created for this study and, therefore, is not validated for general population. The parents will also complete the Montreal Children Feeding scale based on their memories.

The Montreal Children Feeding scale is a validated parental self-questionnaire, allowing the screening of feeding and eating disorders in children under 6 years old. Since the study specific questionnaire is not validated, 60 non-ARFID controls will be included in the study for questionnaires completion. The research also focuses on the psychopathological profile of these adolescents with ARFID regarding their degree of anxiety, their degree of depression, their possible autistic traits and their sensory sensitivity. These aspects will be studied by validated self- and hetero-questionnaires standardized for these fields. The emotional expression of the parents will be assessed during a brief qualitative interview type "Five-Minute Speech Sample".

Study Type

Observational

Enrollment (Actual)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75019
        • Hôpital Robert Debré
      • Paris, France, 75015
        • Hôpital Necker - Enfants Malades
      • Paris, France, 75014
        • Hopital Cochin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adolescents diagnosed with ARFID less than 2 years before

Description

Inclusion Criteria:

For all patients:

  • Adolescent aged 12 to 18 (minors = 17 years 11 months)
  • No opposition from parents and adolescent

For ARFID patients:

  • Consulting at MDA or Necker for an ARFID diagnosed using DSM V criteria
  • Whose first consultation for this disorder was less than 2 years ago

For non-ARFID patients:

  • Consulting or hospitalized in orthopaedic surgery at Necker Hospital or Robert Debré Hospital for an acute traumatic reason
  • Not diagnosed with a chronic illness

Exclusion Criteria:

For all patients:

- Parents and adolescents who do not speak French well enough to understand the questions on the scales and questionnaires

For ARFID patients:

- Diagnosis of autism spectrum disorder already made at the time of the consultation

For non-ARFID patients:

- Presence of a chronic organic or psychological illness, to limit the risk of including non ARFID patients at high risk of eating disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ARFID adolescents
Children between 12 and 17 years old diagnosed with ARFID less than 2 years prior
Questionnaire completion
Non ARFID adolescents
Children between 12 and 17 years old with no organic or psychological illness diagnosed
Questionnaire completion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of pediatric feeding disorders (PFD)
Time Frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent FPD before the age of 4 years compared to adolescents without ARFID by using the Montreal scale score (61 or more) and/or the specific study questionnaire (at least 4 positive answers)
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of eating disorders on growth consequences in ARFID adolescents
Time Frame: 1 day
Evaluation of growth effects of ARFID by measuring the Z score and Tanner stage.
1 day
Sensory profile in ARFID adolescents
Time Frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent hypersensoring or hyposensoring traits compared to adolescents without ARFID by using Sensoring Processing Scale Inventory (SPSI)
1 day
Anxiety in ARFID adolescents
Time Frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent anxiety compared to adolescents without ARFID by using the GAD-7 scale (score of 5 or more)
1 day
Depression in ARFID adolescents
Time Frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent depression compared to adolescents without ARFID by using the ADRS (Adolescent Depression Rating Sclale) (score of 4 or more)
1 day
Autistic traits in ARFID adolescents
Time Frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent autistic traits compared to adolescents without ARFID by using the Autism Spectrum Screening Questionnaire (ASSQ) (score of 13 or more)
1 day
Parental profile in ARFID adolescents
Time Frame: 1 day
Compare parent's emotional expression for adolescents recently diagnosed with ARFID to adolescents without ARFID by using the five minute speech sample.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 3, 2025

Primary Completion (Actual)

February 3, 2025

Study Completion (Actual)

May 2, 2025

Study Registration Dates

First Submitted

October 24, 2024

First Submitted That Met QC Criteria

October 28, 2024

First Posted (Actual)

October 30, 2024

Study Record Updates

Last Update Posted (Actual)

May 6, 2026

Last Update Submitted That Met QC Criteria

April 30, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Avoidant and Restrictive Food Intake Disorders

Clinical Trials on Questionnaire

Subscribe